Current National Institute for Health and Care Excellence (NICE) guidance allows GPs to prescribe memantine for moderate-to-severe Alzheimer’s disease (AD) in patients already taking an acetylcholinesterase inhibitor (AChEI) without referral to secondary care. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.